|
|
|
| Effect of Poge Jiuxin Decoction combined with β-blocker on the treatment of angina pectoris of coronary heart disease with qi stagnation and blood stasis syndrome and its anti-oxidation ability |
| SHU Lili1 SONG Yingjing2 SHAO Yunfei3 |
1.Graduate School, Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou 310053, China;
2.Department of Cardiovascular Medicine, Linhai Hospital of Traditional Chinese Medicine Medical and Health Service Community, Zhejiang Province, Linhai 317000, China;
3.Department of Cardiovascular Medicine, Sanmen People’s Hospital, Zhejiang Province, Sanmen 317100, China
|
|
|
|
Abstract Objective To explore the effect of Poge Jiuxin Decoction combined with β-blocker on the treatment of angina pectoris of coronary heart disease with qi stagnation and blood stasis syndrome and its anti-oxidation ability. Methods A total of 168 patients with angina pectoris of coronary heart disease with qi stagnation and blood stasis syndrome were selected from the Linhai Hospital of Traditional Chinese Medicine Medical and Health Service Community of Zhejiang Province from March 2019 to March 2021, and they were divided into β-blocker group, Poge Jiuxin Decoction group, and combined drug group according to random number table method, with 56 cases in each group. Brain natriuretic peptide (BNP), cardiac troponin I(cTnI), creatine kinase-MB (CK-MB), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide (NO), superoxide dismutase (SOD), malondialdehyde (MDA), glutathione peroxidase (GSH-Px), lipid hydroperoxide (LPO), traditional Chinese medicine syndrome score, and traditional Chinese medicine syndrome efficacy were observed in the three groups before treatment and two weeks after treatment. Results After treatment, the levels of BNP, cTnI, and CK-MB in the three groups were lower than before treatment, and those in the combined drug group were lower than those in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05). After treatment, the levels of TNF-α and IL-6 in the three groups were lower than before treatment, and those in the combined drug group were lower than those in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05); the level of NO in the three groups was higher than that before treatment, and that in the combined drug group was higher than that in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05). After treatment, the levels of SOD and GSH-Px in the three groups were higher than before treatment, and those in the combined drug group were higher than those in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05); the levels of MDA and LPO in the three groups were lower than before treatment, and those in the combined drug group were lower than those in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05). After treatment, the scores of angina pectoris, limb numbness, subcutaneous ecchymosis, and emotional abnormality in the three groups were lower than before treatment, and those in the combined drug group was lower than those in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05). The curative effect of traditional Chinese medicine syndrome in the combined drug group was higher than that in the β-blocker group and the Poge Jiuxin Decoction group (P＜0.05). Conclusion Qi stagnation and blood stasis syndrome patients with angina pectoris of coronary heart disease by the combination of the Poge Jiuxin Decoction and β-blocker can effectively improve the myocardial injury and inflammation of the body, enhance the antioxidant capacity, and achieve good results in clinical treatment.
|
|
|
|
|
|
[1] Dibben G，Faulkner J，Oldridge N，et al. Exercise-based cardiac rehabilitation for coronary heart disease [J]. Cochrane Dat- abase Syst Rev，2021，11（11）：CD001800.
[2] Tu M，Jiang Y，Yu J，et al. Acupuncture for treating chronic stable angina pectoris associated anxiety and depression： A systematic review and meta-analysis [J]. Complement Ther Clin Pract，2021，45：101484.
[3] Wang JS，Yu XD，Deng S，et al. Acupuncture on treating angina pectoris：A systematic review [J]. Medicine （Baltimore），2020，99（2）：e18548.
[4] Ayyasamy L，Bagepally BS. Cost-utility of Ranolazine for Chr- onic Stable Angina Pectoris：Systematic Review and Meta- analysis [J]. Clin Ther，2023，45（5）：458-465.
[5] Li P，Xin Q，Hui J，et al. Efficacy and Safety of Tongxinluo Ca- psule as Adjunctive Treatment for Unstable Angina Pectoris： A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J]. Front Pharmacol，2021，12：742978.
[6] 王新亮.酒石酸美托洛尔缓释片联合阿司匹林对冠心病心绞痛患者QT离散度、血清细胞因子水平的影响[J].检验医学与临床，2022，19（15）：2131-2134.
[7] 尹彬，谢陈玲. 厄贝沙坦氢氯噻嗪联合β-受体阻滞剂治疗重症慢性心力衰竭患者的临床疗效分析[J].国际检验医学杂志，2020，41（2）：197-200，204.
[8] 李娟，蓝纯英，郭敏，等. 破格救心汤联合五苓散治疗气虚血瘀型心力衰竭的临床效果[J].中西医结合心脑血管病杂志，2023，21（2）：337-340.
[9] 中华医学会，中华医学会临床药学分会，中华医学会杂志社，等.稳定性冠心病基层合理用药指南[J].中华全科医师杂志，2021，20（4）：423-434.
[10] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：67-69.
[11] 国家中医药管理局.中医病证诊断疗效标准[S].北京：中国医药科技出版社，2012：125-127.
[12] 中华中医药学会.冠心病稳定型心绞痛中医诊疗专家共识[J].中医杂志.2018，59（5）：447-449.
[13] 杨蓓，李婕，郑建鹏.复方丹参注射液对冠心病心绞痛患者血脂代谢的影响[J].实用临床医药杂志，2020，24（2）：91-93.
[14] 周小玲，杜艳华，陈晓辉，等.补阳还五汤联合阿托伐他汀治疗冠心病心绞痛的临床研究[J].中西医结合心脑血管病杂志，2020，18（4）：650-652.
[15] 刘崇霞，高群，孙小艳，等.硝酸异山梨酯联合麝香保心丸治疗冠心病心绞痛临床效果观察[J].临床军医杂志，2020，48（2）：181-182.
[16] 郑立文，刘晨，姜丽艳，等.苦碟子注射液治疗冠心病心绞痛[J].长春中医药大学学报，2019，35（4）：667-669.
[17] 卢婧，王晓静，谭海龙，等.参芍片联合酒石酸美托洛尔片对冠心病心绞痛患者氧化应激、血管内皮功能和心肌损伤标志物的影响[J].现代生物医学进展，2022，22（20）：3882-3886.
[18] 李先芳，林璋，洪玲.麝香保心丸联合曲美他嗪治疗冠心病心绞痛临床观察[J].中国药业，2019，28（24）：66-68.
[19] 刘美云，郭文丽.心肌复极异常心电图表现与冠心病病人AST、CK、CK-MB及LDH水平的相关性[J].中西医结合心脑血管病杂志，2019，17（14）：2154-2156.
[20] 孙静，王文杰，李丹丹，等.双和散加减治疗冠心病疗效及对抗氧化能力等相关指标变化的研究[J].中华中医药学刊，2021，39（4）：74-76.
[21] 冯晓迪，王东雁，刘守亮，等.大株红景天注射液与芪苈强心胶囊对冠心病心绞痛患者的影响[J].西部中医药，2020，33（1）：106-110.
[22] 于宁，王彦红.自拟安心汤协定方对冠心病患者血清氧化应激指标及HCY、D-二聚体、LP（a）水平的影响[J].世界中医药，2018，13（9）：2216-2219，2223.
[23] 穆少宁，温明馨，吴春燕.丹参多酚酸盐联合艾司洛尔在老年冠心病心绞痛患者中的应用效果[J].中国当代医药，2022，29（15）：55-58.
[24] 李兰霞，王东雁，王蒙，等.红景天注射液与芪苈强心胶囊对冠心病心绞痛患者抗氧化应激指标及心功能的影响[J].中国中西医结合急救杂志，2022，29（1）：53-56.
[25] 邱丹，王凡，赵涛.丹参多酚酸盐治疗冠心病心绞痛的疗效及其对血液流变学、氧化应激的影响[J].安徽医药，2018，22（1）：147-151.
[26] 龚显田，陈丽梅，李子才，等.瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛临床研究[J].陕西中医，2021， 42（7）：886-889. |
|
|
|
